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ABSTRACT
Migraine is a commonly-occurring primary headache disorder that can be extremely
disabling. Despite its prevalence and impact, migraine remains under-recognized and undertreated. The US Headache Consortium recommended validated screening measures as one way
to improve headache diagnosis. Previous studies have sought to determine optimal symptom
algorithms for differentiating migraine from other types of headache or to validate migraine
screening measures, but few studies have attempted to do both.
The current study attempted to statistically determine the most sensitive and specific
symptoms for differentiating between migraine and other headache and validate the resulting
symptom algorithm as a screening measure. Young adults who suffered from migraine (Group 1)
and other headache (Group 2), based on their responses on a computerized diagnostic interview,
served as participants. The total sample consisted of 1,829 participants (71.5% female; 74.4%
white; mean age = 19.09 years [SD = 2.05]) who suffered from some type of headache, which
was split randomly into experimental and validation samples. One hundred fifty-eight (8.6%)
individuals met diagnostic criteria for migraine and 1,104 (60.3%) met for another type of
headache.
Headache duration of 4-72 hours (100%), severity ≥ 5 (91%), photophobia (90%), and
phonophobia (90%) showed the highest sensitivity, while vomiting (98%), duration of 4-72
hours (92%), nausea (89%), and headache-related disability (88%) showed the highest
specificity. Symptoms that did not show either a positive likelihood ratio > 4.5 or negative
likelihood ratio < 0.25 were eliminated. A backward stepwise logistic regression analysis was
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performed on the remaining symptoms and resulted in an optimal model of duration of 4-72
hours, nausea, photophobia, and phonophobia. ROC curve analyses showed that these items had
an optimal operating point (OOP) of 3 out of 4 symptom endorsements, showing a sensitivity of
94%, a specificity of 92%, and an AUC of 93% (+LR = 12.37, -LR = 0.06, PPV = 67%, NPV =
99%).
The current migraine screener performed much better than previous screening measures
and has utility in identifying migraine among non-clinical and young adult samples. Potential
uses of this screening measure are discussed, as are limitations of the current study and possible
future directions.
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CHAPTER 1

INTRODUCTION
Migraine Diagnosis and Burden
Migraine is a commonly-occurring primary headache disorder that can be extremely
disabling and can have a major impact on many areas of an individual’s life. The diagnostic
criteria for migraine are outlined in the 2004 International Headache Society’s (IHS)
International Classification of Headache Disorders, Second Edition (ICHD-II; Headache
Classification Subcommittee of the IHS, 2004). Migraine is defined as “a recurrent headache
disorder manifesting in attacks lasting 4-72 hours” either untreated or unsuccessfully treated
(IHS, 2004, p. 24). Typical characteristics of migraine include unilateral location,
pulsating/throbbing quality, moderate or severe intensity, aggravation by or avoidance of routine
physical activity, and association with nausea and/or vomiting and/or photophobia and
phonophobia (IHS, 2004). Migraine can be divided into two major sub-types: migraine without
aura (1.1) and migraine with aura (1.2). Though less common than migraine without aura,
migraine with aura is characterized by neurological symptoms (i.e., aura) that are usually visual
in nature and typically precede the other features of migraine. (See Appendix B for full criteria
for migraine with and without aura).
In the United States, migraine has a one-year prevalence of 17.1% for women and 5.6%
for men (Lipton et al., 2007) and a lifetime prevalence of approximately 43% for women and
18% for men (Stewart, Wood, Reed, Roy, & Lipton, 2008). Data from the World Health
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Organization indicate that migraine is the third most common medical condition on the planet
(Vos et al., 2012) and among the top 20 diseases worldwide that cause disability (WHO, 2013).
In the US, migraine is responsible for approximately 113 million missed workdays annually,
resulting in the loss of more than $13 billion each year (Stewart, Ricci, Chee, Morganstein, &
Lipton, 2003). As such, migraine diagnosis and treatment research is of great importance in order
to help alleviate this societal and individual burden.
Poor Recognition and Treatment of Migraine
Although migraine is the leading reason for neurologist visits in the United States
(Bekkelund & Albretsen, 2002; Carson, Ringbauer, MacKenzie, Warlow, & Sharpe, 2000),
migraine remains under-recognized, under-diagnosed, and under-treated. Lipton, Amatniek,
Ferrari, and Gross (1994) purported that one of the main barriers to the treatment of migraine
was failure to provide an accurate diagnosis (thus precluding adequate treatment) for those who
consult a physician. Approximately half of migraineurs never receive a diagnosis from a
physician, and of those who do, one-third do not receive adequate treatment (Lipton, Stewart, &
Simon, 1998; Lipton et al., 1994; Lipton, Diamond, Reed, Diamond, & Stewart, 2001; Lipton et
al., 2002). In one Seattle-based study, primary care physicians correctly diagnosed less than 50%
of migraineurs (Stang & VonKorff, 1994).
Migraine remains under-diagnosed for many reasons, one of which may be because the
migraine diagnostic criteria have had poor uptake by physicians due to the number of symptoms
needing assessment (Martin, Penzien, Houle, Andrew, & Lofland, 2005). Although the best
method of identifying migraine would be to assess each of the ICHD-II criteria using a structured
diagnostic interview (Andrew, Penzien, Rains, Knowlton, & McAnulty, 1992), clinic settings
often do not afford time for an interview of this type. Multiple medical problems are often
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assessed during a single primary care office visit, the average time of which is only 11- 20
minutes in the United States (Carr-Hill, Jenkins-Clarke, Dixon, & Pringle, 1998; Mechanic et al.,
2001). Furthermore, the presence of multiple headache types (e.g., migraine and tension-type
headache [TTH]) within an individual, which occurs in up to 51% of headache sufferers (Stang
& Von Korff, 1994), makes it even less likely that migraine will be diagnosed (Lipton et al.,
1994). Another reason that migraine remains under-diagnosed is because many physicians are
uncomfortable evaluating headache patients due to fears about overlooking the headache with a
sinister cause (Detsky et al., 2006). Although headache due to a more serious neurological
condition is only present in 1% of those with chronic headache, this concern can often lead to the
overuse of neuroimaging and prolong visit times (Detsky et al., 2006). In addition to these
barriers, migraine remains under-diagnosed also because most individuals with migraine do not
seek treatment for their migraine, likely as a function of their gender (i.e., men tend to seek
treatment less frequently than women), the severity of their headache, insurance status, and other
economic factors (Lipton et al., 2003; Lipton et al., 2013). Migraine under-diagnosis has several
negative consequences and can be improved through effective screening.
Need for Effective Migraine Screening
Poor diagnostic recognition contributes to inadequate treatment and can contribute to
higher headache-related disability and poorer health-related quality of life (Lipton et al., 2002).
The US Headache Consortium recommended that one way to improve diagnosis of headache in
primary care is the use of validated screening instruments (Dowson, Lipscombe, Sender, Rees, &
Watson, 2002). A brief screening tool could help by increasing the speed and efficiency of
migraine diagnosis, thus identifying individuals needing treatment and at high risk for other
comorbidities (Lipton, Bigal, Amatniek, & Stewart, 2004). Migraine is often comorbid with
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other disorders, such as depression, anxiety, epilepsy, and stroke (Lipton & Silberstein, 1994),
and comorbidity is but one of the reasons that recognizing migraine early in its progression is of
importance. Such is the primary goal of screening programs.
In addition, because migraine may be a progressive disease among some individuals
(Bigal & Lipton, 2006), the aim of migraine screening is the early identification of individuals
with migraine in order to treat current pain and prevent future pain and disability (Lipton et al.,
2004). Migraine-screening measures can be viewed as a low-cost, time-effective means of
disease detection. Effective screening can reduce the direct (e.g., medical care costs) and the
indirect costs of migraine (e.g., unemployment, underemployment, missed work) (Lipton &
Silberstein, 2001; Solomon, 1997; Stewart, Lipton, & Simon, 1996; Von Korff, Stewart, Simon,
& Lipton, 1998). For decades, researchers have attempted to develop brief algorithms and
screening measures for more efficient migraine identification within primary care and neurology
clinic settings.
Statistics Used in Screening Instrument Literature
Statistics that are often reported in migraine identification studies of this type include
sensitivity, specificity, positive and negative predictive values (PPV and NPV), and positive and
negative likelihood ratios (+LR and –LR). Sensitivity (true positives) is the proportion of
migraineurs correctly identified by the screening measure. If sensitivity is low, people with
migraine will be missed. Specificity (true negatives) refers to people without migraine who are
classified by the screener as negative for migraine. If specificity is low, people who do not have
migraine will be classified as migraineurs. A sensitivity and specificity of 50% or 0.5 would
mean the screening instrument is no better than chance at accurately classifying migraine status.
In clinical practice, developers of screening instruments typically emphasize sensitivity over
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specificity so as not to overlook individuals with the disease in question (Altman & Bland,
1994a).
Predictive values, unlike sensitivity and specificity, are influenced by the prevalence of
the disease in the population of interest. If examining a population with a high prevalence of
migraine (such as a headache clinic), the probability is higher that those who screen positive for
migraine will actually have migraine. Whereas sensitivity and specificity answer the question “If
the patient does or does not have the disease, how likely is he/she to have a positive or negative
test?,” the predictive values answer the question, “If the patient has a positive or negative test,
how likely is he/she to have or not have the disease?” The PPV is the number of true-positives
divided by the sum of all positive results (true-positives and false-positives combined), and the
NPV is the number of true-negative results divided by the sum of all negative results (truenegative and false-negative results combined). A high PPV indicates a strong likelihood that a
person who screened positive has migraine, whereas a low PPV is usually found in samples with
low prevalence of migraine. An ideal PPV and NPV would be 100% or 1.0 (Altman & Bland,
1994b; Smith, Winkler, Fryback, 2000).
Likelihood ratios consider the pre-test probability of having a disease and, based on the
results of the diagnostic test or screener, determine how much the probability of the disease
increase or decreases. +LRs reflect how much the probability of disease increases if the
diagnostic test is positive and -LRs reflect how much the probability of disease decreases if the
diagnostic test is negative. An LR > 1 indicates an increased probability that the disorder is
present, while an LR < 1 indicates a decreased probability that the disorder is present. An LR >
10 reflects a large and often conclusive increase in the probability that the disorder is present, 510 a moderate increase, 2-5 a small increase, 1-2 a minimal increase, and 1 reflects no change.
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An LR of 0.5-1 reflects a minimal decrease in the probability that the disorder is present, 0.2-0.5
a small decrease, 0.1-0.2 a moderate decrease, and < 0.1 reflects a large and often conclusive
decrease in the probability that the disorder is present (Grimes & Schulz, 2005; Jaeschke, Guyatt,
& Sackett, 1994).
Symptom Algorithms Most Predictive of Migraine
Past attempts to improve the diagnosis of migraine have included statistical identification
of symptoms most predictive of migraine in a given sample (algorithm studies), as well as the
development of questionnaires that assess for migraine symptoms (screener-validation studies).
Much research has been conducted on the subject but methods and findings are variable, and few
studies have yielded brief migraine screening measures that have been subsequently employed in
clinical practice.
In 2000, Smetana performed a meta-analysis of headache studies that attempted to
determine which clinical features best distinguished migraine from TTH. This meta-analysis
included seminal algorithm studies by Rasmussen, Jensen, and Olesen (1991), Henry et al.
(1992), Michel et al. (1993), and Tom et al. (1994), among others. All studies included in this
meta-analysis reported the most sensitive and specific migraine symptoms but did not attempt
subsequently to validate these as part of a screening measure. (Studies attempting to validate
screening measures are mentioned later in this literature review.) Smetana separated the findings
of his meta-analysis into studies that used IHS diagnostic criteria and those that used other
criteria before the development of the 1988 IHS criteria. Both types of studies produced similar
findings: nausea showed the highest sensitivity (81%) and specificity (96%) for predicting
migraine, followed by photophobia (79%, 86%), phonophobia (67%, 87%), aggravation by
physical activity (81%, 78%), unilateral location (65%, 82%), and pulsating quality (73%, 75%).
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Some of Smetana’s findings would be replicated in subsequent similar studies; however, findings
from many symptom algorithm studies often differ from one another, likely as a function of
differing methodologies, different samples employed, and different comparison groups.
In 2006, Detsky et al. (2006) conducted a systematic review of the migraine diagnostic
literature employing both algorithm studies as well as screener-validation studies. They excluded
more than half of identified relevant studies (n = 7) for the following reasons: 1) Two studies
evaluated migraine symptom clusters that were very similar to the full IHS criteria and, therefore,
were not “screening” measures (Rasmussen, 1991; Tom et al. 1994). (These studies were
included and evaluated as part of the Smetana [2000] meta-analysis.) 2) One study included only
migraine patients and therefore had no estimate of specificity because it lacked a control group
(Cady, Borchert, Spalding, Hart, & Sheftell, 2004). 3) Two studies evaluated migraine symptom
clusters that consisted of only two questions, one of which was “have you ever had migraine?”
(Gervil, Ulrich, Olesen, & Russell, 1998; Maizels & Burchette, 2003). 4) One study sought to
compare headache diary diagnoses to a clinical interview without presenting rates of individual
migraine symptoms (Russell et al., 1992). 5) One study included no quantitative information
regarding sensitivity or specificity of migraine symptoms (Merikangas, Dartigues, Whitaker, &
Angst, 1994). As a result of these exclusions, Detsky and colleagues’ analysis included only one
symptom study and three screener-validation studies, the latter of which are described in detail
later (Lainez et al., 2005; Lipton et al., 2003; Pryse-Phillips et al., 2002).
The symptom study Detsky et al. (2006) reviewed was published by Michel et al. (1993).
This study assessed for migraine symptoms in a French non-treatment-seeking headache sample.
They sought to determine which migraine symptoms best differentiated migraine from “nonmigraine headache” (unspecified). They found that the most sensitive migraine symptoms in this
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population were headache duration (74%), photophobia/phonophobia (66%), unilateral location
(65%), and pulsating quality (64%). The most specific symptoms, on the other hand, were
nausea/vomiting (93%), unilateral location (85%), pulsating quality (83%), disturbance of daily
activities (76%; sometimes referred to as migraine-related disability and not a diagnostic
criterion per se), and aggravation by physical activity (73%). Contrary to Smetana (2000), the
authors of this review concluded that headache duration (4-72 hours) and disturbance of daily
activity were among the most useful symptoms for discriminating between migraine and nonmigraine headache. Based on their review, Detsky et al. (2006) espoused that the mnemonic
device of POUND (Pulsating, duration of 4-72 hOurs, Unilateral, Nausea, Disabling) should be
used for differentiating migraine from non-migraine headache. If 4 of these 5 criteria were met,
the +LR for definite or possible migraine was 24 [95% CI = 1.5-388], and if 3 of the 5 criteria
were met, the +LR was 3.5 [1.3-9.2].
In a more recent study not included in either the Smetana (2000) or Detsky et al. (2006)
review, Wang and colleagues (2008) sought to evaluate the diagnostic sensitivity of each ICHDII criterion within a Taiwanese neurology patient sample. They found that moderate to severe
intensity (97%), nausea/vomiting (67%), and disability (65%) were the symptoms with the
highest sensitivity, while photophobia (91%), nausea/vomiting (86%), phonophobia (79%),
aggravation by physical activity (71%), and disability (70%) had the highest specificity in
differentiating migraine, including “probable” episodic migraine (i.e., meeting all but one
diagnostic criteria for migraine), from non-migraine headache (unspecified). They found that the
optimal symptom cluster was nausea/vomiting, photophobia, and moderate to severe intensity
(sensitivity = 73%, specificity = 82%, PPV = 91%, +LR = 4.06, -LR = .33). The second best
model was nausea/vomiting, photophobia, and disability (sensitivity = 56%, specificity = 88%,
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PPV = 92%, +LR = 4.67, -LR = 0.50), identical to the items that comprise the ID MigraineTM
(Lipton et al., 2003). These findings differed from previously mentioned studies in that moderate
to severe intensity was among the most sensitive and specific symptoms in differentiating
migraine from non-migraine headache.
Other than Michel et al. (1993), a more recent study by Martin, Penzien, Houle, Andrew,
and Lofland (2005) is the only other study published to date that has examined headache in nontreatment-seeking sample. They sought to distinguish migraine (including probable migraine or
“migrainous headache”) from non-migraine headache, such as TTH, cluster headache,
medication overuse headache (MOH), chronic daily headache (CDH), and posttraumatic
headache. In addition to 680 patients from headache and neurology clinics, Martin and
colleagues also evaluated 784 community members and 99 college students. Data on the nonclinical population were collected from 1989-1999. The college sample (M age = 27.8, 67%
female) showed a migraine prevalence rate of 33%, with 8 headache days per month as the
average. Within the college sample, nausea was the best indicator of migraine (+LR = 11.3, -LR
= 0.35, PPV = 85%, NPV = 85%) followed by a combination of nausea, photophobia, and
pulsating quality (+LR = 9.1, -LR = 0.3, PPV = 83%, NPV = 87%, AUC = 86%) and nausea,
photophobia, and aggravation by physical activity (+LR = 22.3, -LR = 0.34, PPV = 92%, NPV =
85%, AUC = 87%). Although this sample was not seeking treatment, similar to that of Michel et
al. (1993), the findings differed in that unilateral location and headache duration were not
important discriminators of migraine, thus showing that methodological and sample differences
(such as differences in comparison groups) may influence differing conclusions. However,
nausea consistently appears within the algorithm literature as an important discriminator of
migraine.
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Symptom-Based Screening Measures
As a supplement to research attempting to identify brief algorithms for migraine
diagnosis, studies have also attempted to validate brief screening measures. In one of the first
international attempts to employ a migraine screening instrument, Gervil, Ulrich, and Olesen
(1998) administered four questions (process of selection unknown) by telephone to a large
sample of Danish twins. The questions were: 1) “Have you ever had a migraine?” 2) “Have you
ever had severe headache accompanied by nausea?” 3) “Have you ever had severe headache
accompanied by hypersensitivity to sound and light?” 4) “Have you ever had visual disturbances
lasting 5-60 minutes followed by headache?” Endorsement of all 4 items showed a sensitivity of
85% and a specificity of 81% (PPV = 49%, NPV = 86%) in differentiating migraine from nonmigraine (TTH), but the authors did not report the psychometric properties of the individual
items. One limitation of this study was that Questions 2 and 3 were not able to identify any more
migraineurs than were identified by Question 1 alone. In addition, the fourth question (which
assessed aura) incorrectly identified 62 migraineurs who were not classified as having aura by
the ICHD criteria as well as 88 non-migraineurs; a total of 45% of individuals who responded to
this question were incorrectly screened as having migraine with aura. As such, this questionnaire
is not psychometrically sound and has not been employed in any other published studies to date.
In a more widely referenced study conducted outside the United States, Pryse-Phillips
and colleagues (2002) assessed for migraine symptoms in a Canadian neurology sample (N =
461). They attempted to identify symptoms that were best able to differentiate migraine from
TTH. They found that the three symptoms of daily occurrence (reportedly used to rule-out
migraine rather than diagnose migraine), unilateral location, and functional impairment
(disability) best differentiated migraine from TTH. They subsequently developed a screening
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measure from these three symptoms and administered it to 178 different neurology patients. The
sensitivity of the three-item measure was 86%, and the specificity was 73% (PPV = 96%, NPV =
38%). This study was unlike others in that the authors chose to include a screening item that
functioned to rule-out migraine rather than identify migraine. In addition, this is one of the only
studies that did not include nausea as an important differentiating symptom of migraine.
In one of the first and most well-known migraine screener studies conducted within the
United States, Lipton and colleagues (2003) developed what is now the most widely-used
screening measure for migraine, the ID MigraineTM. The ID MigraineTM is a three-item selfreport measure used to screen for migraine in a primary care setting. Lipton and colleagues first
administered a 9-item measure of candidate symptoms to patients and retained those that were
best at discriminating migraine from other types of headache (not specified). The most sensitive
migraine symptoms were nausea (81%), photophobia (74%), and aura (74%). The most specific
migraine symptoms were moderate to severe pain (94%), pulsating quality (87%), headacherelated disability (any one-day limitation in activities in the past 3 months; 87%), phonophobia
(83%), photophobia (75%), and unilateral location (75%). The three final items retained for the
ID MigraineTM (by way of backward logistic regression analysis) assess for symptoms of nausea,
sensitivity to light, and headache-related disability, with only one symptom (i.e., disability)
matching the results of Pryse-Phillips et al. (2002). Positive endorsement on two or more of the
three items is considered a positive screen for migraine, having a sensitivity of 81% [77%-85%]
and a specificity of 75% [64%-84%] (PPV = 93%, +LR = 3.2 [2.7-3.9], –LR = 0.25 [0.22-0.28]).
The ID MigraineTM has been validated in samples in different countries (Brighina et al.,
2007; Gil-Gouveia & Martins, 2010) and within the US (Kim & Kim, 2006; Siva et al., 2008; Di
Paolo, Di Nunno, Vanacore, & Bruti, 2009). Furthermore, two Turkish studies and one Brazilian
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study have employed the ID MigraineTM to determine migraine prevalence among students
(Bicakci et al., 2008; Domingues et al., 2011; Oztora et al., 2011) but did not attempt to validate
the screener against a gold standard diagnosis. As such, the ID MigraineTM has never been
validated within a student sample, and its diagnostic utility with non-treatment-seeking young
adult headache sufferers remains undetermined.
In the same year, Maizels and Burchette (2003) sought to assess not only migraine, but
also daily headache syndromes, medication overuse, and disability within a medical population.
Their Brief Headache Screen (BHS) consists of seven questions, the diagnostic portion of which
consists of three items: 1) “How often do you have headaches?” 2) “How often do you have
severe headaches (disabling)?” 3) “How often do you take headache relievers or pain
medicines?”. The respondent provides an answer to each item from the options: daily or near
daily, 3-4 days/week, 2/week-2/month, 1/month or less, or almost never. Question 1 showed a
sensitivity of 85% for identifying migraine when answered with anything other than daily or
near daily or almost never and 98% when answered with anything other than almost never. The
corresponding specificities were much lower (63% when answered almost never or daily or near
daily and 29% when answered almost never). Maizels and Burchette did not report the sensitivity
and specificity of Questions 1 and 2 combined because their goal was to differentiate episodic
headache from chronic headache rather than differentiating migraine from other headache types.
The BHS has limited use as a migraine screening measure, because it is lengthier than most
others (7 items total), its format and scoring more complex, and its psychometric properties
poorer than those of other validated measures.
Cady et al. (2004) attempted to validate a 3-Question Headache Screen in a large sample
of adult migraineurs. Although the method of item selection is unknown, the questions were: 1)
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“Do you have recurrent headaches that interfere with work, family, or social functions?” 2)
“Does your headache last at least 4 hours?” 3) “Have you had new or different headaches in the
past 6 months?” A diagnosis of migraine was suggested by a yes answer to questions 1 and 2 and
a no answer to question 3. Migraineurs were recruited for this study using one of three methods:
ICHD criteria (1988), physician’s clinical impression, or presence of recurring disabling
headaches. The 3-item screener (with a positive response to questions 1 and 2 and a negative
response to question 3) identified migraine in 78% of patients meeting ICHD-II criteria. Among
the entire sample, Question 2 (duration over 4 hours) was endorsed by 94.7% of migraineurs.
Although not part of the screening measure, the symptoms of nausea (86%), photophobia (90%),
and phonophobia (74%) were commonly reported in the diagnostic recruitment portion of the
study. The use of this instrument is limited as its specificity in differentiating migraine from nonmigraine headache is unknown and because its reported psychometric properties are lower than
those of other similar instruments. In addition, although nausea and photophobia were commonly
reported migraine symptoms, the authors did not indicate how these items performed (in
differentiating migraine from other headache) nor explain why these items were not included in
the screening measure.
Lainez and colleagues (2005) endeavored to identify migraine in a non-treatment-seeking
sample that included individuals with migraine and those with other types of headache
(predominantly TTH). They conducted their study in two stages. The initial version of the
measure contained 15 questions based on the 1988 IHS diagnostic criteria. Of the original 15
candidate questions, logistic regression analyses identified four optimal questions: 1) “Do you
have frequent or intense headaches?” 2) “Do your headaches usually last more than 4 hours?” 3)
“Do you usually suffer from nausea when you have a headache?” 4) “Does light or noise bother
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you when you have a headache?” In the second stage, the authors added a fifth question related
to headache disability and administered this final questionnaire (Migraine Screening
Questionnaire; MS-Q) to 137 migraineurs. A positive screen on 4 of 5 questions showed a
sensitivity of 92% [87%-99%], specificity of 81% [72%-91%], PPV of 83% [75%-91%], NPV of
92% [85%-99%], +LR of 4.99 [3.04-8.19], and –LR of .09 [0.04-0.21]. The authors have since
validated their questionnaire within a primary care setting (82% sensitivity, 97% specificity, PPV
= 95%, NPV = 94%; Lainez et al., 2010). The MS-Q inquires about three additional migraine
symptoms not in the ID Migraine (headache duration, intensity, and phonophobia) and is the
only published questionnaire that was based from an algorithm and validated in a non-treatmentseeking sample of migraineurs. As such, its findings have not been replicated.
Need for the Current Study
In consideration of extant literature, the current study was needed for several reasons.
First, methodological and comparison group differences between migraine studies (algorithm
and screener-validation studies) limit replicability and comparability and are likely the main
reasons for differing findings. Second, most of the previous literature has focused on
discriminating migraine from other chronic headache syndromes likely to be represented in
medical settings, but little research has been conducted in non-clinical samples that contain a
high proportion of individuals with episodic TTH (ETTH), as well as individuals with chronic
headache types. Lastly, although some studies have sought to create screening algorithms for
identifying migraine and other studies have sought to validate migraine screening measures,
rarely has the same study sought to both identify a brief algorithm for migraine and validate that
algorithm as a screening measure.
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One of the biggest methodological differences in the algorithm literature is that whereas
some research reports on optimal “clusters” of symptoms for differentiating migraine
(considering both the sensitivity and specificity of each item), other studies only provide
information for those items that are the most sensitive versus those that are the most specific,
without considering which items may constitute an optimal model for discriminating migraine
from non-migraine headache. Additional limitations are that studies of screener validation often
do not report how screener items were initially selected and comparison groups are not often
described. With regard to meta-analyses and reviews, these varying methods within the
culminating studies often are not taken into account before combining and reporting on their
general findings. This likely is the main reason for disparate findings between studies, metaanalyses, and reviews.
The only migraine symptom that has shown to be an important discriminator of migraine
across most studies is nausea, likely because individuals with other types of headache almost
never experience nausea. Other symptoms of migraine, however, are less unique. For example,
although photophobia, phonophobia, aggravation by physical activity, pulsating quality, and
unilateral location are often present in migraine (and are, in some combination, required for a
diagnosis of migraine), these symptoms can also be present in other headache syndromes.
With regard to sample differences, most research on migraine symptomatology to date
has been conducted within headache clinics or primary care settings. Despite what is known
about the large proportion of migraineurs who do not seek treatment or obtain an adequate
diagnosis, few researchers have sought to identify the most relevant migraine symptoms within a
non-treatment-seeking population. In addition, despite knowledge that incidence of migraine
begins to rise most dramatically during young adulthood (Lipton, Bigal, Hamelsky, & Scher,
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2008), that migraine prevalence among college students is approximately 25% (Bigal, Bigal,
Betti, Bordini, & Speciali, 2001; McDermott, Peck, Walters, & Smitherman, 2013; Smitherman,
McDermott, & Buchanan, 2011), and that the disability among these migraineurs is significant
(Smitherman et al., 2011; Walters, Hamer, & Smitherman, 2014), only one study to date has
attempted to identify the most predictive migraine symptomatology within a young adult sample
(Martin et al., 2005). Notably, the student sample within the Martin et al. (2005) study was quite
small (N = 99).
The current study attempted to differentiate migraine from other headache types within a
non-treatment-seeking sample of individuals. ETTH (headache characterized by mild to
moderate bilateral pressure on both sides of the head) is the most common headache disorder in
the world (Fumal, & Schoenen, 2008; Stovner et al., 2007; WHO, 2013) but, unless very
frequent, is uncommon in clinical settings due to its relatively mild presentation. The inclusion of
these individuals (in addition to those with more chronic headache, such as medication overuse
headache [MOH], cluster headache, and chronic TTH) in the current study may result in a
different symptom model than previous literature.
Finally, as mentioned above, few studies have both developed an algorithm for diagnosis
and validated the algorithm as a screening measure. Although studies by Pryse-Phillips et al.
(2002) and Lipton et al. (2003) attempted to do both, each study has shortcomings that limit the
measures’ use in other populations and for purposes other than those originally intended. For
example, the validation sample within the Pryse-Phillips study was relatively small (N = 128),
and inclusion of a screening item that was used to rule-out rather than “rule-in” migraine
complicates scoring and screening. In addition, their findings that left out nausea as an important
discriminator of migraine call into question the study’s methodological integrity. Respondents
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within the ID MigraineTM validation sample were pre-selected only if they were in an early
symptomatic phase of migraine but had not yet presented to their physician, thus greatly limiting
generalizability to the broader population. Although the ID MigraineTM measure has since been
validated in other samples, it is unclear to what degree the uniqueness of the original validation
sample affected the properties of the screening instrument. Further, the disability item included
in both the screening measures developed by Pryse-Phillips et al. and Lipton et al. is not a
diagnostic criterion of migraine and may also be present in those with other chronic headache
types (Schwartz, Stewart, Simon, & Lipton, 1998). As such, specificity of the ID MigraineTM
was found to be lower than desired (75%), as was test-retest reliability (kappa = 0.68). Due to
these shortcomings of the two studies that have employed both algorithm development and
screener-validation, more research is needed to develop a sensitive and specific brief screening
measure for migraine diagnosis.
The current study first attempted to determine statistically the most sensitive and specific
ICHD-II migraine symptoms for differentiating migraine from other headache types within a
non-clinical population (i.e., algorithm development). As a supplement to the work of Martin et
al. (2005), the current study then attempted to validate this algorithm of symptoms within a
holdout sample from the larger overall sample (i.e., screener validation) and identify an optimal
cut-off point for use. As previous literature suggests, nausea was hypothesized to be the strongest
discriminator of migraine followed (in no particular order) by photophobia and/or phonophobia,
and aggravation by physical activity. However, because findings vary regarding optimal
discriminatory migraine symptoms, no a priori hypotheses were made about other candidate
symptoms such as unilateral location, duration of 4-72 hours, or pulsating quality.
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CHAPTER 2

METHODS
Participants
Participants were undergraduate students at the University of Mississippi who
participated in exchange for modest psychology course credit. They completed an online battery
of measures beginning in the fall of 2011 and ending in the winter of 2013. For preliminary
analyses, those meeting ICHD-II diagnostic criteria for episodic migraine (with or without aura)
or chronic migraine comprised the migraine group, while those with episodic, chronic, or
probable TTH, cluster headache, posttraumatic headache, medication overuse headache, or those
who complained of headache but could not be classified comprised the non-migraine group. For
supplementary analyses, probable migraineurs (i.e., meeting all but one diagnostic criteria for
migraine) were included as part of the migraine group.
Measures
Structured Diagnostic Interview for Headache-Revised (SDIH-R). Included in the
computerized battery of measures were questions from the computer-validated Structured
Diagnostic Interview for Headache (SDIH; Andrew et al., 1992), which was modified to comport
fully with current ICHD-II criteria. The computer-administered SDIH-R includes ten questions
for diagnosing migraine without aura, one question assessing for headache frequency, two
questions assessing for aura symptoms, five questions assessing for other headache disorders
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(posttraumatic, cluster, and medication overuse headache), and a question about headacherelated disability (Appendix C).
Procedures and Statistical Analyses
As mentioned above, the current study occurred in two phases. The dataset was randomly
split by approximately 50%, with SDIH-R responses from the first half of participants (i.e.,
experimental sample) used for algorithm development and from the second half of participants
(i.e., validation sample”) used for screener validation.
First, chi-square analyses and independent t-tests were performed to confirm that the
experimental and validation samples did not significantly differ from one another on
demographic variables, headache type, average headache days per month, or average headache
severity. For algorithm development, two-by-two tables were constructed using each of the
migraine symptoms (present vs. absent) and headache diagnoses (migraine vs. non-migraine).
The sensitivity, specificity, predictive values, and likelihood ratios were calculated for each of
the migraine symptoms. Receiver-operator characteristic (ROC) curves were then plotted for
each of the one-variable migraine symptom models in order to determine which symptoms were
most predictive of a migraine diagnosis, as provided by the area under the curve (AUC). The
ROC curve plots reflected the extent to which the symptom in question differed in prevalence
among people who have migraine versus another type of headache. Next, using the optimal
model guidelines in Martin et al. (2005), symptoms were eliminated if they did not have +LRs >
4.5 or –LRs < 0.25. A backward stepwise logistic regression analysis was then performed using
the remaining variables to determine the optimal model for differentiating migraine from nonmigraine headache. The resulting model was used as the screening measure validated in the next
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phase of the study. The optimal symptom model was also explored (supplementary to the main
analyses) with the inclusion of probable migraineurs.
For screener validation, two-by-two tables were constructed using each possible cut-off
point of the screening measure and headache diagnosis, from which sensitivity, specificity, LRs
and PVs were calculated. An ROC curve then was plotted in order to determine the correlation of
the screening measure with the gold standard diagnosis (AUC estimations) and the measure’s
utility in differentiating migraine from other headache types as applied to the holdout validation
sample. The ROC curve was used to analyze all possible cut-off points of the new screener and
was used to determine the optimal operating point (OOP) of the screener (Halpern, Albert,
Krieger, Metz, & Maidment, 1996). The OOP attempts to give the best trade-off between the
costs of failing to detect positives and the costs of raising “false alarms.” The internal
consistency (Cronbach’s alpha coefficient) of the new screening measure was also determined
from the ROC curve analysis. Finally, the psychometric properties of the screening measure
were examined as a function of gender and race. Although the screening measure was not
designed to identify probable migraineurs, the utility of the screener was also examined within
these individuals to supplement the main analyses.

	
  

20	
  

CHAPTER 3

RESULTS
Data Analytic Assumptions
Histograms, Q-Q plots, and descriptive statistics data (i.e., skewness, kurtosis) were used
to assess data analytic assumptions. The average number of headache days per month and
average headache severity was normally distributed. No outliers were found on the variables of
interest.
Sample Comparison
The total sample consisted of 1,966 participants who responded positively to the initial
question “Do you ever get headaches?” Excluding 137 with missing data, 1,829 were classified
into 10 headache categories (see Appendix A Table 1) based on their responses to the SDIH-R.
The sample of 1,829 was split randomly by approximately 50% to ensure equivalence between
the experimental (n = 887) and validation (n = 942) samples. Non-significant chi-square tests
(for gender, race [white vs. non-white], and headache category) and independent samples t-tests
(for age, headache frequency, and headache severity) confirmed that the two samples did not
differ significantly on any of these variables (see Appendix A Tables 1-3).
Phase I: Experimental Sample and Algorithm Development
Characteristics of the Experimental Sample
Participants in the experimental sample were 70.8% female and 74.5% white, with a
mean age of 19.05 (SD = 1.96). Sixty-nine (7.8%) participants met ICHD-II diagnostic criteria
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for migraine (chronic or episodic with or without aura), thus comprising the migraine group, and
552 (62.2%) met diagnostic criteria for another type of headache, thus comprising the nonmigraine group. In addition, 266 (30.0%) met criteria for probable migraine. They were excluded
from primary analyses in order to comport strictly with the ICHD-II diagnostic criteria for
migraine, but they were included as part of the migraine group in supplementary analyses.
Episodic migraineurs with aura (n = 17) and without aura (n = 29) within the
experimental sample reported an average of 6.94 (SD = 3.09) and 7.76 (SD = 5.60) headache
days per month, respectively, while chronic migraineurs (n = 23) reported an average of 18.61
(SD = 4.07) headache days per month. The average number of headache days per month reported
by all migraineurs (11.17 [SD = 6.98]) was significantly higher than the average number of
headache days per month reported by individuals with non-migraine headache (5.29 [SD = 4.72];
t(619) = -9.20, p < .001). Average headache severity was not significantly different between
chronic (M = 6.13, SD = 1.06) and episodic (M = 6.37, SD = 1.60) migraineurs, t(67) = 0.65, p =
.518; however, as expected migraineurs reported significantly higher pain severity (6.29 [SD =
1.44]) than did individuals with non-migraine headache (3.88 [SD = 1.62]; t(619) = -11.76, p <
.001).
Algorithm Development
Within the experimental sample, the performance of each migraine symptom was
compared to the gold standard diagnosis of migraine as acquired via the SDIH-R. Two-by-two
tables were created showing the number of migraineurs and non-migraineurs endorsing each
symptom (see Appendix A Table 4), from which sensitivity, specificity, positive and negative
likelihood ratios, and positive and negative predictive values were calculated (see Appendix A
Table 5). Headache duration of 4-72 hours showed the highest sensitivity (100%), followed by
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severity ≥ 5 (91%), photophobia (90%), and phonophobia (90%). In contrast, vomiting showed
the highest specificity (98%), followed by duration of 4-72 hours (92%), nausea (89%), and
disability (defined as headaches interfering with work, school, or personal life; 88%).
ROC curves were then plotted in order to determine which symptoms were best at
differentiating migraine from other headache types (see Appendix A Table 5). Duration of 4-72
hours had the largest AUC (96%), followed by photophobia (78%), severity ≥ 5 (78%), and
nausea (77%). Next, unilateral location, pulsing quality, and worsening by physical activity were
ruled-out as part of the optimal model as they did not have an +LR > 4.5 or –LR < 0.25. The
remaining 7 symptoms (i.e., duration of 4-72 hours, severity ≥ 5, nausea, vomiting, photophobia,
phonophobia, and disability) were entered in a backward stepwise logistic regression analysis to
determine the optimal model for distinguishing migraine from other headache types. The
retained optimal model consisted of duration of 4-72 hours (B = 21.08), nausea (B = 1.18),
photophobia (B = 1.87), and phonophobia (B = 1.54). This model was validated as a screening
measure in the next phase of the study.
Using the same procedures delineated above, analyses were repeated when including
probable migraineurs as part of the migraine sample (see Appendix A Table 6). When including
those with probable migraine in the migraine group, duration of 4-72 hours no longer displayed
the greatest sensitivity. Instead, photophobia showed the highest sensitivity (90%), followed by
phonophobia (89%), pulsing quality (77%), and severity ≥ 5 (73%). AUCs were also different
from the original model; photophobia showed the highest AUC (78%), followed by phonophobia
(72%), nausea (70%), and severity ≥ 5 (69%) (see Appendix A Table 7). Optimal likelihood
ratios when including those with probable migraine were found for nausea (B = 1.77) and
photophobia (B = 2.73). Because this was a supplementary aim of the present study, validation
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was not attempted on this 2-symptom model. Instead, the validity of the original 4-symptom
screener was explored within probable migraine sufferers in subsequent validation analyses.
Phase II: Validation Sample and Screener Validation
Characteristics of the Validation Sample
Participants in the validation sample were 72.2% female and 74.2% white, with a mean
age of 19.12 (SD = 2.13). Eighty-nine (9.4%) participants met ICHD-II diagnostic criteria for
migraine (chronic or episodic with or without aura), thus comprising the migraine group, and 552
(58.6%) met diagnostic criteria for another type of headache, thus making up the non-migraine
group. In addition, 301 (32.0%) met criteria for probable migraine and were explored as part of
the migraine group in supplementary analyses.
Episodic migraineurs with aura (n = 26) and without aura (n = 45) within the validation
sample reported an average of 6.65 (SD = 3.43) and 6.29 (SD = 3.28) headache days per month,
respectively, while chronic migraineurs (n = 18) reported an average of 18.44 (SD = 4.66)
headache days per month. The average number of headache days per month reported by all
migraineurs (8.85 [SD = 6.04]) was significantly higher than the average number of headache
days per month reported by individuals with non-migraine headache (5.46 [SD = 4.87]; t(639) = 5.89, p < .001). Average headache severity was not significantly different between chronic (M =
6.78, SD = 1.35) and episodic (M = 5.99, SD = 1.66) migraineurs, t(87) = -1.87, p = .065;
however, as expected migraineurs reported significantly higher pain severity (6.15 [SD = 1.63])
than did individuals with non-migraine headache (3.81 [SD = 1.64]; t(638) = -12.49, p < .001).
Screener Validation
To validate the prior 4-factor model as a screening algorithm in the holdout validation
sample, two-by-two tables were created for each possible cut-off point of the screener (see

	
  

24	
  

Appendix A Table 8), from which sensitivity, specificity, positive and negative likelihood ratios,
and positive and negative predictive values were calculated (see Appendix A Table 9). The OOP
for the screener was positively endorsing 3 out of 4 items. This OOP had a sensitivity of 94%
and a specificity of 92% (+LR = 12.37, -LR = .06, PPV 67%, NPV 99%). ROC curve analyses
were used to determine the correlation of each cut-off point with the gold standard diagnosis of
migraine (see Appendix A Table 9). The AUC of positively endorsing 1 or more items was 69%
[95% CI: 65-74%], of 2 or more items was 87% [85-90%], of 3 or more items was 93% [9096%], and of all 4 items was 78% [72-85%]. When including probable migraineurs, the 4-item
screener showed an OOP of responding positively to 2 or more items (AUC = 87% [84-89%];
see Appendix A Table 11). All items in the screening algorithm were significantly intercorrelated
(rs from .18 to .51, ps ≤ .01) and were highly correlated with the OOP of the screener (rs from
.42 to .71, ps ≤ .01). The internal consistency (Cronbach’s alpha) for this measure was .60.
Group Differences in Screener Performance
As shown in Appendix A Table 12, the screening measure performed better statistically
among men than in women at all 4 cut-off points; however this statistically significant difference
is almost certainly a function of the large sample size and not clinically meaningful, as the AUC
at the OOP of the screener was 94% among men versus 93% among women) The screener
performed equally well among white and non-white individuals (see Appendix A Table 13).
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CHAPTER 4

DISCUSSION
The current study sought to identify an algorithm for migraine diagnosis and to validate
this algorithm as a screening instrument in a non-treatment-seeking sample of young adults.
Previous studies within this area of study rarely have attempted to accomplish both these goals
within the same sample, and prior research of this type varies widely with regard to
methodology, comparison groups, and results. Duration of 4-72 hours, nausea, photophobia, and
phonophobia composed the optimal model for differentiating migraine from non-migraine
headache and showed high sensitivity, specificity, and correlation with the gold standard
diagnosis at the OOP. The screening measure was not as well able to differentiate migraine from
non-migraine headache when including probable migraineurs but still proved useful at
distinguishing migraine (when including probable migraineurs) at a different OOP.
The screening measure had very strong clinical utility among men and women and
among white and non-white individuals at its optimal operating point. Although the internal
consistency (Cronbach’s alpha) for this measure was poor, this finding is not surprising given the
few number of items retained and their lack of redundancy; this does not preclude its use given
the purpose of the measure (Tavakol & Dennick, 2011). In general, the current findings
confirmed the a priori hypotheses and resemble findings of extant literature.
Migraine Prevalence
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The prevalence rate of migraine within the current study (8.6%) was lower than that
suggested by previous literature conducted within the same population (Smitherman et al., 2011;
Walters et al., 2014). These studies found that approximately one quarter of college students met
criteria for episodic migraine. However, these studies extended migraine duration to two hours
instead of four, and thus included probable migraineurs. When including probable migraineurs in
the current sample, prevalence rises to approximately 40%, which more closely matches the
findings of Martin and colleagues (2005), who found a prevalence rate of 33% (including
probable migraineurs) in a college sample. Another possible explanation for the disparity in
prevalence could be the difference in methodology used for diagnosing headache. For example,
Smitherman et al. and Walters et al. employed the same computer-administered diagnostic
interview as the current study, but the former studies administered the interview in-person, rather
than online. This in-person method allowed for more clinical judgment regarding diagnosis, as
well as the ability for clarification and follow-up questions, whereas the computer-administered
version of the diagnostic criteria in the current study did not allow for this type of follow-up and
was more rigid in diagnosis.
Comparison to previous findings
In the current study, duration of 4-72 hours, severity ≥ 5, photophobia, and phonophobia
showed the highest sensitivity, while vomiting, duration of 4-72 hours, nausea, and disability
showed the highest specificity. Ultimately, the 10 migraine symptoms were effectively reduced
to a 4-item screener including the symptoms of duration of 4-72 hours, nausea, photophobia, and
phonophobia. These findings are generally similar to those of most previous studies, but this is
the first study to find this unique combination of duration of 4-72 hours, nausea, photophobia,
and phonophobia as an effective screener for migraine. The meta-analysis by Smetana (2000);
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the review by Detsky et al. (2006); and studies by Michel et al. (1993), Wang et al. (2008),
Martin et al. (2005), Lipton et al. (2003), Cady et al. (2004), and Lainez et al. (2005) all found
that nausea and photophobia were among the most sensitive and specific symptoms for
distinguishing migraine from other headache types. In addition, five of these studies also found
phonophobia to be one of the most sensitive and specific symptoms for identifying migraine
(Cady et al., 2004; Lainez et al., 2005; Michel et al., 1993; Smetana, 2000; Wang et al., 2008),
but it was included as part of the optimal model in only one of these studies (Lainez et al., 2005).
The main difference in findings between the current study and previous literature is that
of duration being an important differentiator of migraine in combination with these other
symptoms. While Detsky et al. (2006), Michel et al. (2006), and Cady et al. (2004) found
duration to be one of the most important distinguishers of migraine, the other aforementioned
studies did not have these same findings. This disparity in findings is most likely due to the
difference in comparison groups among the studies. Studies by Wang et al. (2008) and Martin et
al. (2005) indicated that their migraine samples included probable migraineurs, while the metaanalysis by Smetana (2000) likely also included probable migraineurs (although it was unclear
from the methods). As noted earlier, younger probable migraineurs often endorse shorter-thantypical headache duration (i.e., under 4 hours), and thus may mitigate the importance of duration
in differentiating migraine from non-migraine headache. This rationale is strengthened by the
present finding that duration showed poor sensitivity when including probable migraineurs (27%
vs. 100% without probable migraineurs).
Another notable difference between this study and others is the lack of predictive
importance of disability within the current study. Studies that found disability to be an important
predictor of migraine, such as those by Wang et al. (2008), Cady et al. (2004), and Lipton et al.
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(2003), were inconsistent in how disability was defined, and therefore, their findings regarding
the utility of this variable cannot be directly compared. In addition, these studies were conducted
with treatment-seeking samples that are overall more likely to endorse a greater level of
disability, while the current study was conducted using a comparison group of individuals having
numerous forms of primary and secondary headaches and thus varying levels of disability.
Implications of the current findings
The OOP of the current 4-question screener was a positive endorsement on 3 or more
items, showing 94% sensitivity and 92% specificity. The current screener outperformed the ID
MigraineTM (81% sensitivity, 75% specificity; Lipton et al., 2003), the 3-item screener developed
by Cady et al., 2004 (77% sensitivity), the screener recommended by Pryse-Phillips et al. (2002)
(86% sensitivity and 73% specificity), and even a longer measure, the MS-Q (92% sensitivity
and 81% specificity; Lainez et al., 2005). The screener also performed well among probable
migraineurs, showing a sensitivity of 98% and specificity of 75% at its OOP (positively
endorsing at least 2 out of 4 items). Although the current screener appears to be extremely
accurate at differentiating migraine from other headache and may be especially useful clinically,
screeners are often best used among the population in which they are developed until further
validation assesses their utility in other populations.
The use of this screening measure within a non-treatment-seeking sample could help to
identify individuals with migraine who have not previously been diagnosed by a healthcare
professional. Early diagnosis is essential to adequate treatment for migraine (Lipton et al., 1994)
and early diagnostic screening is one of the best ways to reduce societal burden and cost, as well
as individual burden, disability, and chronification of headache over time (Dowson et al., 2002;
Lipton & Silberstein, 2001; Lipton et al., 2002, 2004; Solomon, 1997; Stewart et al., 1996; Von
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Korff et al., 1998). This screener may prove to be useful in differential diagnosis for individuals
with multiple headache types (Stang & VonKorff, 1994) and could help to identify those at risk
for other comorbidities (Lipton et al., 2004), although these possibilities await empirical
verification.
Limitations and Future Directions
Some limitations of the current study and screener exist. One main limitation is that the
authors did not re-administer independently to the holdout sample the 4 items that comprised the
screening measure. Although there is not yet any evidence to suggest that symptom endorsement
would differ if the screening measure was administered in isolation (versus with other items), the
possibility exists and awaits empirical confirmation. In addition, as mentioned above, headache
sufferers in the current study were diagnosed using a computerized questionnaire, which does not
allow for inquiry or clarification of responses, as does an in-person interview. Future research
should attempt to validate this screening measure in this same population by administering the
screener and comparing results to gold standard diagnosis as assigned by in-person diagnostic
interviews.
Future research should also attempt to validate this measure within a treatment-seeking
sample. Preliminary findings suggest that this measure could be extremely useful in
differentiating migraine from other headaches in non-treatment-seeking young adults; however,
the use of this screener does not have to be limited to this population. Further attempts to validate
this screening measure in other samples could expand its usefulness to clinical populations.
Because physicians often do not have time to assess all diagnostic criteria or conduct a lengthy
structured interview (Martin et al., 2005), the inclusion of this 4-item measure could be used to
identify a large proportion of migraineurs that are often not diagnosed (Lipton et al., 2002; Stang
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& VonKorff, 1994). In addition to clinical uses, the screener could also be used in research
studies to more accurately estimate the prevalence rate of migraine in a given population.
Finally, head-to-head comparisons of this screener and other widely used migraine screening
measures are warranted. Collectively, this study and future validation efforts will clarify the
potential utility of this promising screener.
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Table 1
Demographics and Headache Diagnoses

Experimental
Sample
n = 887

Validation
Sample
n = 942

P=

Entire
Sample
N = 1,829

Demographics
Age M (SD)
19.05 (1.96)
19.12 (2.13)
.476
19.09 (2.05)
Gender
.511
Female
628 (70.8%)
680 (72.2%)
1,308 (71.5%)
Male
259 (29.2%)
262 (27.8%)
521 (28.5%)
Race
.877
White
661 (74.5%)
699 (74.2%)
1,360 (74.4%)
Black
147 (16.6%)
184 (19.5%)
331 (18.1%)
Other
79 (8.9%)
59 (6.3%)
138 (7.5%)
Headache Type
CM
23 (2.6%)
18 (1.9%)
.325
41 (2.2%)
EM w/out aura
29 (3.3%)
45 (4.8%)
.102
74 (4.0%)
EM w/aura
17 (1.9%)
26 (2.8%)
.234
43 (2.4%)
Migraine
69 (7.8%)
89 (9.4%)
.137
158 (8.6%)
*PM
*266 (30.0%)
*301 (32.0%)
*.364
*567 (31.0%)
CTTH
12 (1.4%)
16 (1.7%)
.547
28 (1.5%)
ETTH
184 (20.7%)
177 (18.8%)
.294
361 (19.7%)
PTTH
219 (24.7%)
203 (21.5%)
.111
422 (23.1%)
Cluster
18 (2.0%)
18 (1.9%)
.855
36 (2.0%)
Posttraumatic
40 (4.5%)
52 (5.5%)
.323
92 (5.0%)
MOH
1 (0.1%)
1 (0.1%)
.966
2 (0.1%)
No Diagnosis
78 (8.8%)
85 (9.0%)
.863
163 (8.9%)
Non-Migraine
552 (62.2%)
552 (58.6%)
.137
1,104 (60.4%)
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type
headache; MOH = Medication overuse headache
*Probable migraineurs were excluded from the preliminary analyses, but were included as part of
the migraine group in secondary analyses
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Table 2
Mean Headache Days Per Month (0-30)

Headache Type

Experimental
Validation
P=
Entire Sample
Sample
Sample
N = 1,829
n = 887
n = 942
CM
18.61 (SD = 4.07)
18.44 (4.66)
.905
18.54 (4.28)
EM w/out aura
7.76 (5.60)
6.29 (3.28)
.159
6.86 (4.37)
EM w/aura
6.94 (3.09)
6.65 (3.43)
.782
6.77 (3.27)
PM
7.27 (5.53)
7.38 (5.90)
.831
7.33 (5.72)
CTTH
16.67 (3.26)
18.94 (5.54)
.218
17.96 (4.77)
ETTH
4.91 (3.41)
4.85 (2.91)
.844
4.88 (3.17)
PTTH
5.03 (4.76)
5.16 (4.17)
.766
5.09 (4.48)
Cluster
9.67 (5.25)
8.78 (5.02)
.607
9.22 (5.08)
Posttraumatic
7.53 (5.47)
8.13 (6.46)
.633
7.87 (6.03)
*MOH
17
25
NA
21 (5.66)
No Diagnosis
2.83 (3.00)
2.34 (1.80)
.207
2.57 (2.45)
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type
headache; MOH = Medication overuse headache
*MOH sufferers could not be compared on average headache days per month because there were
only two MOH sufferers.
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Table 3
Mean Headache Severity (0-10)

Headache Type

Experimental
Validation
P=
Entire Sample
Sample
Sample
N = 1,829
n = 887
n = 942
CM
M = 6.13 (SD = 1.06)
6.78 (1.35)
.093
6.41 (1.22)
EM w/out aura
6.48 (1.77)
5.73 (1.76)
.079
6.03 (1.79)
EM w/aura
6.18 (1.29)
6.42 (1.39)
.562
6.33 (1.34)
PM
5.24 (1.60)
5.15 (1.65)
.540
5.19 (1.63)
CTTH
5.33 (1.23)
4.44 (1.21)
.065
4.82 (1.28)
ETTH
4.01 (1.43)
3.88 (1.28)
.366
3.95 (1.36)
PTTH
3.67 (1.47)
3.68 (1.49)
.909
3.67 (1.48)
Cluster
5.28 (1.99)
5.50 (1.82)
.729
5.39 (1.89)
Posttraumatic
5.10 (1.85)
5.12 (1.87)
.969
5.11 (1.85)
MOH
5
9
NA
7 (2.83)
No Diagnosis
3.00 (1.60)
2.65 (1.50)
.148
2.82 (1.55)
CM = Chronic migraine; EM = Episodic migraine; PM = Probable migraine; CTTH = Chronic
tension-type headache; ETTH = Episodic tension-type headache; PTTH = Probable tension-type
headache; MOH = Medication overuse headache
*MOH sufferers could not be compared on average headache severity because there were only
two MOH sufferers.
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Table 4
Experimental Sample: 2X2 Symptom Tables for Each Migraine Symptom (n = 621 with
headache)

Migraine (excluding PM)
Yes
No
42
510
552

Duration (4-72 hours)

Present
Not Present
Total

69
0
69

Unilateral

Present
Not Present
Total

34
35
69

211
339
550

Pulsing

Present
Not Present
Total

55
14
69

279
272
551

Severity ≥ 5

Present
Not Present
Total

63
6
69

194
358
552

Worsened by activity

Present
Not Present
Total

53
15
69

180
372
552

Nausea

Present
Not Present
Total

45
24
69

61
491
552

Vomiting

Present
Not Present
Total

13
56
69

11
539
550

Photophobia

Present
Not Present
Total

62
7
69

180
363
543

Phonophobia

Present
Not Present
Total

62
7
69

246
306
552

	
  

46	
  

Disability

	
  

Present
Not Present
Total

44
25
69
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65
482
547

Table 5
Experimental Sample: Migraine Symptom Performance

Sensitivity
100%
(95% CI:
95-100)
49%
(37-62%)

Specificity +LR
Duration (492%
13.14
72 hrs)
(90-94%)
(9.8317.58)
Unilateral
62%
1.28
(57-66%)
(.991.67)
Pulsing
80%
49%
1.57
(68-88%)
(45-54%)
(1.361.82)
Severity ≥ 5
91%
65%
2.60
(82-97%)
(61-69%)
(2.272.97)
Worsened by 78%
67%
2.39
activity
(66-87%)
(63-71%)
(2.012.85)
Nausea
65%
89%
5.90
(53-76%)
(86-91%)
(4.407.91)
Vomiting
19%
98%
9.42
(11-30%)
(96-99%)
(4.3920.20)
Photophobia 90%
67%
2.71
(80-96%)
(63-71%)
(2.353.13)
Phonophobia 90%
55%
2.02
(80-96%)
(51-60%)
(1.782.28)
Disability
64%
88%
5.37
(51-75%)
(85-91%)
(4.027.17)
CI = Confidence Interval; Prevalence = 11%
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-LR

.82
(.651.05)
.41
(.26.66)
0.13
(.06.29)
.33
(.21.51)
.39
(.28.54)
.83
(.74.93)
0.15
(.08.31)
.18
(.09.37)
.41
(.30.56)

PPV
62%
(5271%)
14%
(1019%)
16%
(1321%)
25%
(1930%)
23%
(1829%)
42%
(3352%)
54%
(3374%)
26%
(2032%)
20%
(1625%)
40%
(3150%)

NPV
100%
(99100%)
91%
(8793%)
95%
(9297%)
98%
(9699%)
96%
(9498%)
95%
(9397%)
91%
(8893%)
98%
(9699%)
98%
(9599%)
95%
(9397%)

AUC
96%
(9598%)
56%
(4963%)
65%
(5871%)
78%
(7383%)
72%
(6679%)
77%
(7084%)
58%
(5066%)
78%
(7383%)
72%
(6778)
76%
(6983)

Table 6
Experimental Sample: 2X2 Symptom Tables for Each Migraine Symptom (including probable
migraineurs) (n = 887 with headache)

Migraine (including PM)
Yes
No
42
510
552

Duration (4-72 hours)

Present
Not Present
Total

91
242
333

Unilateral

Present
Not Present
Total

179
155
334

211
339
550

Pulsing

Present
Not Present
Total

256
78
334

279
272
551

Severity ≥ 5

Present
Not Present
Total

246
89
335

194
358
552

Worsened by activity

Present
Not Present
Total

222
112
334

180
372
552

Nausea

Present
Not Present
Total

167
168
335

61
491
552

Vomiting

Present
Not Present
Total

30
304
334

11
539
550

Photophobia

Present
Not Present
Total

302
33
335

180
363
543

Phonophobia

Present
Not Present
Total

296
38
334

246
306
552
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Disability

	
  

Present
Not Present
Total

131
204
335

50	
  

65
482
547

Table 7
Experimental Sample: Migraine Symptom Performance (including probable migraineurs)

Sensitivity
27% (95%
CI: 23-32)

+LR
-LR
Duration (43.59
.79
72 hrs)
(2.56- (.735.04)
.84)
Unilateral
54%
62%
1.40
0.75
(48-59%)
(57-66%)
(1.21- (.661.62)
.86)
Pulsing
77%
49%
1.51
0.47
(72-81%)
(45-54%)
(1.37- (.381.68)
.58)
Severity ≥ 5
73%
65%
2.09
.41
(68-78%)
(61-69%)
(1.83- (.342.38)
.49)
Worsened by 66%
67%
2.04
0.50
activity
(61-72%)
(63-71%)
(1.77- (.422.35)
.58)
Nausea
50%
89%
4.51
.56
(44-55%)
(86-91%)
(3.48- (.505.85)
.63)
Vomiting
9%
98%
4.49
.93
(6-13%)
(96-99%)
(2.28- (.908.84)
.96)
Photophobia 90%
67%
2.72
0.15
(86-93%)
(63-71%)
(2.40- (.113.08)
.20)
Phonophobia 89%
55%
1.99
.21
(85-92%)
(51-60%)
(1.80- (.152.20)
.28)
Disability
39%
88%
3.29
.69
(34-45%)
(85-91%)
(2.53- (.634.29)
.76)
CI = Confidence Interval; Prevalence = approximately 37%

	
  

Specificity
92%
(90-94%)
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PPV
68%
(6076%)
46%
(4151%)
48%
(4452%)
56%
(5161%)
55%
(5060%)
73%
(6779%)
73%
(5786%)
63%
(5867%)
55%
(5059%)
69%
(6073%)

NPV
68%
(6471%)
69%
(6473%)
78%
(7382%)
80%
(7684%)
77%
(7381%)
75%
(7178%)
64%
(6167%)
92%
(8994%)
89%
(8592%)
70%
(6774%)

AUC
60%
(5664%)
58%
(5462%)
63%
(6067%)
69%
(6673%)
67%
(6371%)
70%
(6573%)
53%
(4957%)
78%
(7581%)
72%
(6875%)
63%
(5967%)

Table 8
Validation Sample: 2X2 Tables of Screener at Different Cut-off Points

Migraine (excluding PM)
Yes
No
329
209
538

1 or more symptoms

Positive screen
Negative screen
Total

87
0
87

2 or more symptoms

Positive screen
Negative screen
Total

87
0
87

136
402
538

3 or more symptoms

Positive screen
Negative screen
Total

82
5
87

41
497
538

All 4 symptoms

Positive screen
Negative screen
Total

50
37
87

5
533
538
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Table 9
Validation Sample: Screener Performance at Different Cut-off Points

1 or
more

Sensitivity Specificity
100% (95% 39%
CI: 96-100) (35-43%)

2 or
more

100%
(96-100%)

75%
(71-78%)

3 or
more

94%
(87-98%)

92%
(90-94%)

All 4

57%
(46-68%)

99%
(98-100%

+LR
1.64
(1.531.75)
3.96
(3.424.57)
12.37
(9.1716.67)
61.84
(25.37150.73)

Disease prevalence = 13%
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-LR

.06
(.03.15)
.43
(.34.55)

PPV
21%
(1725%)
39%
(3346%)
67%
(5875%)
91%
(8097%)

NPV
100%
(98100%)
100%
(99100%)
99%
(98100%)
94%
(9195%)

AUC
69%
(6574%)
87%
(8590%)
93%
(9096%)
78%
(7285%)

Table 10
Validation Sample: 2X2 Tables of Screener at Different Cut-off Points (including probable
migraineurs)

Migraine (including PM)
Yes
No
329
209
538

1 or more symptoms

Positive screen
Negative screen
Total

384
0
384

2 or more symptoms

Positive screen
Negative screen
Total

378
6
384

136
402
538

3 or more symptoms

Positive screen
Negative screen
Total

197
187
384

41
497
538

All 4 symptoms

Positive screen
Negative screen
Total

61
323
384

5
533
538
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Table 11
Validation Sample: Screener Performance at Different Cut-off Points (including probable
migraineurs)

1 or
more

Sensitivity Specificity
100% (95% 39%
CI: 99-100) (35-43%)

2 or
more

98%
(97-99%)

75%
(71-78%)

3 or
more

51%
(46-56%)

92%
(90-94%)

All 4

16%
(12-20%)

99%
(98-100%

+LR
1.64
(1.531.75)
3.89
(3.374.51)
6.73
(4.949.18)
17.09
(6.9342.14)

-LR

.02
(.01.05)
.53
(.47.59)
.85
(.81.89)

Disease prevalence = 42%
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PPV
54%
(5058%)
74%
(7077%)
83%
(7787%)
92%
(8397%)

NPV
100%
(98100%)
99%
(9799%)
73%
(6976%)
62%
(5966%)

AUC
69%
(6673%)
87%
(8489%)
72%
(6875%)
58%
(5461%)

Table 12
Performance of Screener Among Genders

1 or more
Men
- screen
+ screen
AUC

2 or more

3 or more

All 4

77
178
72% (95% CI:
62-83)

137
118
89% (84-94%)

220
35
94% (84-100%)

248
7
70% (51-89%)

Women
- screen
+ screen
AUC

132
535
68% (63-74%)

271
396
86% (83-90%)

464
203
93% (89-96%)

608
59
80% (73-87%)

Chi Square
P=

11.395
=.001

12.824
<.001

26.896
<.001

10.330
=.001

	
  

56	
  

Table 13
Performance of Screener Among Races

1 or more
White
- screen
+ screen
AUC

2 or more

3 or more

All 4

157
529
70% (95% CI:
64-75)

300
386
87% (84-91%)

502
184
93% (89-97%)

634
52
81% (73-89%)

Other
- screen
+ screen
AUC

52
184
68% (59-78%)

108
128
87% (82-93%)

182
54
95% (90-100%)

222
14
72% (59-85%)

Chi Square
P=

.073
.787

.294
.588

1.424
.233

.718
.397
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1. G43

Migraine

1.1 G43.0

Migraine without aura

A. At least 5 attacks fulfilling criteria B–D
B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)
C. Headache has at least 2 of the following characteristics:
1. unilateral location
2. pulsating quality
3. moderate or severe pain intensity
4. aggravation by or causing avoidance of routine physical activity (e.g., walking
or climbing stairs)
D. During headache at least 1 of the following:
1. nausea and/or vomiting
2. photophobia and phonophobia
E. Not attributed to another disorder
1.2. G 43.10

Typical aura with migraine headache

A. At least two attacks fulfilling criteria B-D
B. Aura consisting of at least one of the following, but no motor weakness:
1. Fully reversible visual symptoms including positive features (e.g. flickering
lights, spots or lines) and/or negative features (i.e. loss of vision)
2. Fully reversible sensory symptoms including positive features (i.e. pins and
needles) and/or negative features (i.e. numbness)
3. Fully reversible dysphasic speech disturbance
C. At least two of the following:
1. Homonymous visual symptoms and/or unilateral sensory symptoms
2. At least one aura symptom develops gradually over ≥5 minutes and/or
different aura symptoms occur in succession over ≥5 minutes
3. Each symptom lasts ≥5 minutes and ≥60 minutes
D. Headache fulfilling criteria B-D for 1.1 Migraine without aura begins during the aura
or follows the aura within 60 minutes
E. Symptoms not attributed to another disorder
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APPENDIX C: SDIH-R
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Included are 10 migraine diagnostic questions (marked with *), a question of headache
frequency, two questions assessing for aura symptoms, five questions to assess for other
headaches (posttraumatic, cluster, and medication overuse [MOH]), and a question regarding
disability.
1. Do you ever get headaches?
a. Yes
b. No
2. On average, how many DAYS PER MONTH do you have a headache? (PLEASE ENTER A
NUMBER BETWEEN 0-30)
_____ days
*3. If 0 is no pain, 5 is moderate pain, and 10 is the worst pain imaginable, what is the average
pain intensity of these headaches? (pick one number between 0 and 10)
_____
*4. If left untreated or unsuccessfully treated, about long would these headaches usually last?
a. Less than 30 minutes
b. At least 30 minutes but less than 2 hours
c. At least 2 hours but less than 4 hours
d. Between 4 hours and 3 days
e. Between 3 days and 7 days
f. Longer than 7 straight days
5. For approximately how long have you been having these headaches?
a. Less than 3 months
b. 3 months
c. 4 months or more
*6. How many of these headaches have you had in your life?
a. Less than 5
b. 5 – 9
c. 10 – 20
d. More than 20
*7. Which of the following best describes your pain?
a. Pulsating/Throbbing
b. Tight pressure (non-pulsating)
*8. Is the pain typically experienced on one side or both sides of your head?
a. Typically one side
b. Typically both sides
*9. Is the pain made worse by routine physical activities or cause you to avoid routine physical
activities (like walking, bending over, or climbing stairs)?
a. Yes
b. No
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*10. Do you often feel nauseous or sick to your stomach during these headaches?
a. Yes
b. No
*11. Do you often vomit or throw up during these headaches?
a. Yes
b. No
*12. Are you often sensitive to light during these headaches?
a. Yes
b. No
*13. Are you often sensitive to sound during these headaches?
a. Yes
b. No
14. Do you often experience any symptoms shortly before the headache pain actually begins,
such as changes in your vision (blurry vision, seeing spots or zigzag lines), changes in your
sensation (numbness, tingling), or changes in your speech?
a. Yes
b. No
15. How many times have you experienced these symptoms (i.e., blurry vision, seeing spots or
zigzag lines) before having a headache?
a. 1
b. 2 – 5
c. 6 – 10
d. More than 10
16. Do you use any medications to treat these headaches?
a. Yes
b. No
17. If you use medication, how many days per week do you use any type of medication to treat
your headaches?
a. Less than 1 day per week
b. 1-2 days per week
c. 3 days per week
d. 4 or more days per week
18. How long have you been using these medications at this frequency?
a. 3 months or less
b. More than 3 months
19. Did your headache develop or get worse when you started using these medications at this
frequency?
a. Yes
b. No
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20. Did this headache develop shortly after a head injury or head trauma?
a. Yes
b. No
21. Have you ever been diagnosed with cluster headaches?
a. Yes
b. No
22. Do these headaches interfere with your work, school, or personal life?
a. Yes
b. No
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APPENDIX D: 4-ITEM SCREENING MEASURE

	
  

64	
  

1. If left untreated or unsuccessfully treated, about long would these headaches usually last?
a. Less than 30 minutes
b. At least 30 minutes but less than 2 hours
c. At least 2 hours but less than 4 hours
d. Between 4 hours and 3 days
e. Between 3 days and 7 days
f. Longer than 7 straight days
2. Do you often feel nauseous or sick to your stomach during your headaches?
a. a. Yes
b. No
3. Are you often sensitive to light during your headaches?
a. a. Yes
b. No
4. Are you often sensitive to sound during your headaches?
a. a. Yes
b. No

*An answer of “d” on question 1 indicates migraine while all other responses indicate nonmigraine headache.
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